SMARCA2 and cancer: Furthermore, treatment with CBP/p300 dual inhibitor suppressed the growth of xenografts derived from SMARCA4/SMARCA2-deficient and SS18–SSX fusion cancer cells, resulting from repression of KREMEN2 and induction of apoptosis.